乳がん診断の世界市場レポート 2025年

乳がん診断市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で69億1,000万米ドルに成長します。予測期間の成長は、個別化医療、リキッドバイオプシー、3dマンモグラフィ（トモシンセシス）、AIと機械学習、遠隔医療、遠隔診察に起因すると考えられます。予測期間の主な動向には、画像技術の進歩、個別化医療、リキッドバイオプシー、AIおよび機械学習が含まれます。

乳がん診断市場の成長は、乳がんの罹患率の増加によって牽引されると予想されます。乳がんは最も罹患率の高いがんであり、毎年約210万人の女性が罹患し、女性のがん関連死亡者数が最も多いことから、診断機器に対する需要は増加するとみられています。乳がんの予後を改善し、死亡率を低下させるには、早期発見が最も重要です。例えば、2022年1月、米国がん協会は、2022年の米国における女性の浸潤性乳がんの新規症例数は287,850例、DCISの症例数は51,400例と推定され、乳がん関連の死亡者数は4万3,250人と予想されると報告しています。したがって、乳がんの罹患率の上昇は、乳がん診断市場の活性化につながると予測されます。

乳がんに対する政府の取り組みと資金援助は、乳がん診断市場の成長に貢献する構えです。乳がんの研究、予防、治療を進める上で、政府の支援はイニシアティブや財政的支援を通じて重要な役割を果たしています。これらのプログラムは、乳がんに対する認識を高め、検診やマンモグラフィサービスを通じて早期発見を促進し、乳がん検査や治療を受ける恵まれない地域社会に経済的支援を提供することを目的としています。2022-23年度予算において、オーストラリア政府保健省は、乳がん検診のための専用予算970万米ドルを含む、様々ながん種に対する検査・検診サービスの利用しやすさを向上させるために4,070万米ドルを割り当てた。その結果、政府のイニシアティブと資金調達の取り組みが乳がん診断市場を前進させています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の乳がん診断PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の乳がん診断市場：成長率分析
• 世界の乳がん診断市場の実績：規模と成長, 2019-2024
• 世界の乳がん診断市場の予測：規模と成長, 2024-2029, 2034F
• 世界の乳がん診断総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の乳がん診断市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像診断
• 生検
• ゲノム検査
• 血液検査
• その他のタイプ
• 世界の乳がん診断市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 蛍光in situハイブリダイゼーション（FISH）
• 比較ゲノムハイブリダイゼーション（CGH）
• 免疫組織化学（IHC）
• その他のテクノロジー
• 世界の乳がん診断市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• BRCA乳がん
• ERとPR乳がん
• HER2乳がん
• EGFR変異検査乳がん
• その他のがんの種類
• 世界の乳がん診断市場診断タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イオン化乳房イメージング技術
• 非電離イメージング技術
• 世界の乳がん診断市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• がん研究センター
• 診断検査室
• 外来手術センター
• 世界の乳がん診断市場、イメージングのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マンモグラフィー
• 超音波画像診断
• 磁気共鳴画像法（MRI）
• 陽電子放出断層撮影（PET）
• トモシンセシス
• 世界の乳がん診断市場、生検の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 針生検
• コア針生検
• 細針吸引生検（FNA）
• 定位生検
• 世界の乳がん診断市場ゲノム検査の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンコタイプDX
• マンマプリント
• PAM50
• BRCA1または2検査
• 世界の乳がん診断市場血液検査の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体生検
• 循環腫瘍DNA（ctDNA）検査
• 循環腫瘍細胞（CTC）検査
• 世界の乳がん診断市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン受容体検査
• HER2検査
• 遺伝子変異検査

第7章 地域別・国別分析

• 世界の乳がん診断市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の乳がん診断市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 乳がん診断市場：競合情勢
• 乳がん診断市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GE Healthcare
• Thermo Fisher Scientific Inc.
• Siemens AG
• NanoString Technologies Inc.
• Gamma Medica Inc.
• Aurora Imaging Technology Inc.
• Dilon Technologies Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Micrima Limited
• Provista Diagnostics Inc.
• Leica Biosystems Nussloch GmbH
• bioTheranostics Inc.
• Bio-Rad Laboratories Inc.
• Illumina Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 乳がん診断市場2029：新たな機会を提供する国
• 乳がん診断市場2029：新たな機会を提供するセグメント
• 乳がん診断市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.68 billion in 2024 to $5.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to awareness and screening campaigns, mammography screening, technological advancements, genetic testing, multidisciplinary approach.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine, liquid biopsies, 3d mammography (tomosynthesis), ai and machine learning, telemedicine and remote consultations. Major trends in the forecast period include advancements in imaging technologies, personalized medicine, liquid biopsies, ai and machine learning.

The growth of the breast cancer diagnostics market is expected to be driven by the increasing incidence of breast cancer. With breast cancer being the most prevalent form of cancer, affecting approximately 2.1 million women annually and resulting in the highest number of cancer-related deaths among women, the demand for diagnostic equipment is set to rise. Early detection is paramount in improving the prognosis and reducing the mortality rate associated with breast cancer. For example, in January 2022, the American Cancer Society reported an estimated 287,850 new cases of invasive breast cancer and 51,400 cases of DCIS in women in the United States for 2022, with an expected 43,250 breast cancer-related fatalities. Hence, the escalating incidence of breast cancer is projected to fuel the breast cancer diagnostics market.

Government initiatives and funding for breast cancer are poised to contribute to the growth of the breast cancer diagnostics market. Government support, through initiatives and financial backing, plays a crucial role in advancing breast cancer research, prevention, and treatment. These programs aim to raise awareness, promote early detection through screening and mammography services, and provide financial aid for underserved communities undergoing breast cancer testing and treatment. In the budget for 2022-23, the Australian Government Department of Health allocated $40.7 million to improve the accessibility of testing and screening services for various cancer types, including a dedicated $9.7 million for breast cancer screening. Consequently, government initiatives and funding initiatives are propelling the breast cancer diagnostics market forward.

In the breast cancer diagnostics market, a significant trend is the continuous advancement in technology, which has led to the development of new diagnostic techniques for breast cancer. One notable innovation is 3D mammography, also known as breast tomosynthesis, which captures multiple images of the breast from various angles and constructs a 3-D model. An example of technological innovation in this field is the introduction of Thermalytix by Niramai, an Indian Health-Tech company, in September 2022. Thermalytix is an automated breast cancer screening and diagnostic tool that combines thermal imaging with artificial intelligence to enhance breast cancer detection and diagnosis.

Key players in the breast cancer diagnostics market are actively engaged in the development of cutting-edge AI-based devices designed to improve diagnostic accuracy and drive market revenues. AI breast cancer diagnostic devices leverage artificial intelligence algorithms to analyze complex medical data and offer valuable diagnostic insights and recommendations. By applying machine learning and data processing techniques, these devices can deliver highly accurate and efficient disease identification. For example, Digistain, a biotech company based in the United Kingdom, launched an AI breast cancer diagnostic tool in December 2022, boasting an accuracy rate of over 99%. This technology, validated through clinical studies and peer reviews, not only expedites diagnoses but also enhances treatment decisions. It holds the potential to significantly reduce waiting times, lower costs, and enable personalized risk assessment, potentially eliminating the need for chemotherapy in some cases. Through the application of machine learning and proprietary optical scans, this device can identify intricate patterns that traditional methods may overlook, providing highly personalized risk evaluations validated with a substantial patient sample.

In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition allows Hologic to strengthen its breast surgery portfolio by integrating Endomag's innovative wireless localization and lymphatic tracing technologies. Endomagnetics Ltd., based in the UK, specializes in advanced breast cancer diagnostic solutions, including technologies for tissue localization and lymphatic tracing.

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the broadband internet services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types
• 2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
• 3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Other Cancer Types
• 4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
• 5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
• Subsegments:
• 1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis
• 2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
• 3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
• 4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
• 5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
• Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Diagnostics Market Characteristics

3. Breast Cancer Diagnostics Market Trends And Strategies

4. Breast Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Breast Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Breast Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Breast Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Breast Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Breast Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Breast Cancer Diagnostics Total Addressable Market (TAM)

6. Breast Cancer Diagnostics Market Segmentation

• 6.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging
• Biopsy
• Genomic Tests
• Blood Tests
• Other Types
• 6.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluorescent In Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Immunohistochemical (IHC)
• Other Technologies
• 6.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BRCA Breast Cancer
• ER And PR Breast Cancer
• HER 2 Breast Cancer
• EGFR Mutation Test Breast Cancer
• Other Cancer Types
• 6.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ionizing Breast Imaging Technologies
• Non-ionizing Imaging Technologies
• 6.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Cancer Research Centers
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• 6.6. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Imaging, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammography
• Ultrasound Imaging
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Tomosynthesis
• 6.7. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Needle Biopsy
• Core Needle Biopsy
• Fine Needle Aspiration Biopsy (FNA)
• Stereotactic Biopsy
• 6.8. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Genomic Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncotype DX
• MammaPrint
• PAM50
• BRCA1 Or 2 Testing
• 6.9. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Biopsy
• Circulating Tumor DNA (ctDNA) Tests
• Circulating Tumor Cells (CTCs) Tests
• 6.10. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Receptor Tests
• HER2 Tests
• Genetic Mutation Testing

7. Breast Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Diagnostics Market

• 8.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Diagnostics Market

• 9.1. China Breast Cancer Diagnostics Market Overview
• 9.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Diagnostics Market

• 10.1. India Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Diagnostics Market

• 11.1. Japan Breast Cancer Diagnostics Market Overview
• 11.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Diagnostics Market

• 12.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Diagnostics Market

• 13.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Diagnostics Market

• 14.1. South Korea Breast Cancer Diagnostics Market Overview
• 14.2. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Diagnostics Market

• 15.1. Western Europe Breast Cancer Diagnostics Market Overview
• 15.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Diagnostics Market

• 16.1. UK Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Diagnostics Market

• 17.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Diagnostics Market

• 18.1. France Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Diagnostics Market

• 19.1. Italy Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Diagnostics Market

• 20.1. Spain Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Diagnostics Market

• 21.1. Eastern Europe Breast Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Diagnostics Market

• 22.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Diagnostics Market

• 23.1. North America Breast Cancer Diagnostics Market Overview
• 23.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Diagnostics Market

• 24.1. USA Breast Cancer Diagnostics Market Overview
• 24.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Diagnostics Market

• 25.1. Canada Breast Cancer Diagnostics Market Overview
• 25.2. Canada Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Diagnostics Market

• 26.1. South America Breast Cancer Diagnostics Market Overview
• 26.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Diagnostics Market

• 27.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Diagnostics Market

• 28.1. Middle East Breast Cancer Diagnostics Market Overview
• 28.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Diagnostics Market

• 29.1. Africa Breast Cancer Diagnostics Market Overview
• 29.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Breast Cancer Diagnostics Market Competitive Landscape
• 30.2. Breast Cancer Diagnostics Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. GE Healthcare
• 31.2. Thermo Fisher Scientific Inc.
• 31.3. Siemens AG
• 31.4. NanoString Technologies Inc.
• 31.5. Gamma Medica Inc.
• 31.6. Aurora Imaging Technology Inc.
• 31.7. Dilon Technologies Inc.
• 31.8. Exact Sciences Corporation
• 31.9. F. Hoffmann-La Roche Ltd
• 31.10. Micrima Limited
• 31.11. Provista Diagnostics Inc.
• 31.12. Leica Biosystems Nussloch GmbH
• 31.13. bioTheranostics Inc.
• 31.14. Bio-Rad Laboratories Inc.
• 31.15. Illumina Inc.

32. Global Breast Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

34. Recent Developments In The Breast Cancer Diagnostics Market

35. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Breast Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Breast Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Breast Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer